Effect of compound 11 g as a novel selective cox-2 inhibitor on movement disorders in a rat model of Parkinson's disease

被引：0
作者：
Ardestani, Mehdi Shafiee [1 ]
Moghaddam, Hadi Fathi [2 ]
Saffari, Mostafa [3 ]
机构：
[1] Univ Tehran Med Sci, Dept Med Chem & Radiopharm, Fac Pharm, Tehran, Iran
[2] Joundishapour Univ Med Sci, Sch Med & Phys Res Ctr, Dept Phys, Ahvaz, Iran
[3] Shahid Beheshti Univ Med Sci, Dept Pharmaceut, Fac Pharm, Tehran, Iran
来源：
PAKISTAN JOURNAL OF MEDICAL SCIENCES | 2008年 / 24卷 / 03期
关键词：
compound (11g); celecoxib; electrical lesion; Parkinson's disease; inflammation; cyclooxygenase-2;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Objective: To test the effect of selective COX-2 inhibitors compound 11 g on movement disorders of Parkinson's disease (PD). Methodology: In the study the rat left substantia nigra pars compacta (SNc) has been destroyed using electrical lesion (10 Sec; 1 mA DC) to generate PD model. Then 11 g (2, 4mg/kg) and celecoxib a well known and standard COX-2 inhibitor (4, 8mg/kg) have been administrated orally to parkinsonian rats. Then the rigidity and Locomotor activity of parkinsonian rats were evaluated. Results: Both selective COX-2 inhibitors decreased the rigidity and improved the locomotor activity of parkinsonian rats P<0.05 as compared to the control groups. Conclusions: Based on the results of the Locomotor activity and rigidity tests using parkinsonian rats, we found that compound 11 g had remarkable rigidity-improving effect.
引用
收藏
页码：436 / 441
页数：6
相关论文
共 50 条
  • [31] Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease
    Lenda, Tomasz
    Ossowska, Krystyna
    Berghauzen-Maciejewska, Klemencja
    Matloka, Mikolaj
    Pieczykolan, Jerzy
    Wieczorek, Maciej
    Konieczny, Jolanta
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 910
  • [32] The effect of celecoxib, a selective COX-2 inhibitor, on liver ischemia/reperfusion-induced oxidative stress in rats
    Ozturk, H
    Gezici, A
    Ozturk, H
    [J]. HEPATOLOGY RESEARCH, 2006, 34 (02) : 76 - 83
  • [33] Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease
    Belaid, Hayat
    Adrien, Joelle
    Karachi, Carine
    Hirsch, Etienne C.
    Francois, Chantal
    [J]. SLEEP MEDICINE, 2015, 16 (10) : 1245 - 1251
  • [34] Effect of environmental tobacco smoke on COX-2 and SHP-2 expression in a periodontitis rat model
    Li, Xiangjun
    Liang, Xiangyang
    Li, Shujuan
    Qi, Xia
    Du, Ning
    Yang, Dongru
    [J]. ORAL DISEASES, 2021, 27 (02) : 338 - 347
  • [35] The therapeutic effect of moclobemide, a reversible selective monoamine oxidase a inhibitor, in Parkinson's disease
    Sternic, N
    Kacar, A
    Filipovic, S
    Svetel, M
    Kostic, VS
    [J]. CLINICAL NEUROPHARMACOLOGY, 1998, 21 (02) : 93 - 96
  • [36] Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats
    Takeda, J
    Kitajima, K
    Fujii, S
    Horiuchi, H
    Hori, H
    Chibana, Y
    Okuyama, T
    Tominaga, K
    Ichikawa, K
    Ono, Y
    Teramoto, T
    Ohkura, Y
    Imura, J
    Shinoda, M
    Chiba, T
    Sakamoto, C
    Kawamata, H
    Fujimori, T
    [J]. ONCOLOGY REPORTS, 2004, 11 (05) : 981 - 985
  • [37] Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson's Disease
    Carvalho, Miguel M.
    Campos, Filipa L.
    Marques, Mariana
    Soares-Cunha, Carina
    Kokras, Nikolaos
    Dalla, Christina
    Leite-Almeida, Hugo
    Sousa, Nuno
    Salgado, Antonio J.
    [J]. FRONTIERS IN BEHAVIORAL NEUROSCIENCE, 2017, 11
  • [38] Association between COX-2 G-765C polymorphism and the risk of Alzheimer's disease: a meta-analysis
    Huang, Meimei
    Zhong, Jianping
    Li, Hongzhuang
    Ouyang, Jipeng
    Li, Guoxing
    Li, Yongxin
    You, Wenxia
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07): : 12911 - 12917
  • [39] Beneficial effect of the selective Na+/Ca2+ exchange inhibitor SEA0400 in a mouse model of Parkinson's disease
    Nashida, Tetsuaki
    Fukuda, Sayoko
    Kawasaki, Toshiyuki
    Kitao, Tatsuya
    Ago, Yukio
    Takuma, Kazuhiro
    Matsuda, Toshio
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2008, 128 : 172 - 174
  • [40] Selective COX-2 Inhibitor Etoricoxib's Liposomal Formulation Attenuates M2 Polarization of TAMs and Enhances its Anti-metastatic Potential
    Akif, Usmani Mohammed
    Miyan, Javed
    Rana, Rafquat
    Goswami, Narayan Kumar
    Bhadauria, Smrati
    Chourasia, Manish Kumar
    [J]. PHARMACEUTICAL RESEARCH, 2023, 40 (02) : 551 - 566
12345